mySanAntonio.com |
Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases
mySanAntonio.com It’s been a big couple of years for gene therapies. In December 2017, the FDA approved the first gene therapy, made by Spark Therapeutics, which is used to treat a hereditary form of blindness. Earlier in the year, the FDA approved the first cell … |
Barron’s |
Why the Deal for AveXis Is a Powerful Vote for Replacement Gene …
Barron’s Novartis’s $8.7 billion deal to buy AveXis, one of the leaders in replacement gene therapy, amounts to a strong endorsement of the developing biotechnology. It also looks bullish for Regenxbio, which makes the viral delivery mechanism for AveXis’s … How a Rockville company benefits from Novartis’ $8.7B purchase of a Chicago biotechWashington Business Journal Analyst: AveXis M&A Could Support Interest In RegenxbioBenzinga Zacks Premium Investment Service – Zacks.comZacks SEC.gov all 47 news articles » |
Barron’s |
Why the Deal for AveXis Is a Powerful Vote for Replacement Gene …
Barron’s Novartis’s $8.7 billion deal to buy AveXis, one of the leaders in replacement gene therapy, amounts to a strong endorsement of the developing biotechnology. It also looks bullish for Regenxbio, which makes the viral delivery mechanism for AveXis’s … How a Rockville company benefits from Novartis’ $8.7B purchase of a Chicago biotechWashington Business Journal Zacks Premium Investment Service – Zacks.comZacks X0306 4 2018-03-13 false 0001590877 REGENXBIO Inc. RGNX 0001346164 Simpson Curran C/O REGENXBIO INC …SEC.gov |
Atlanta Journal Constitution |
Even after FDA warnings, stem cell clinics still turning hope into hype
Atlanta Journal Constitution Dr. Mark Berman, of the California-based Cell Surgical Network, collects fat from a patient’s back as part of an experimental stem cell procedure. Berman’s company is one of many for-profit clinics that market stem cells to patients to treat dozens of … It’s all about the (stem cell) neighborhood — ScienceDailyScience Daily The structure and function of a controller of stem cell divisionPhys.Org Are we on the brink of a stem cell revolution? – The TelegraphTelegraph.co.uk The Times –Medical Dialogues all 29 news articles » |
Forbes |
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: ‘A Journey To Focus On Data And Digital’
Forbes This morning, Novartis announced it would buy gene therapy pioneer AveXis for $8.7 billion, giving the Swiss drug giant several treatments for rare diseases that work by inserting new DNA into patients’ cells. AveXis shares rose 78% to nearly match the … Why the Deal for AveXis Is a Powerful Vote for Replacement Gene TherapyBarron’s Why Novartis Is Paying $8.7 Billion for a Gene Therapy Developer You’ve Never Heard OfFortune Novartis enters deal to acquire gene therapy company AveXis for $8.7 billionCNBC Wall Street Journal –USA TODAY –STAT –Zacks all 131 news articles » |
Foreign Affairs |
Media alert: New articles in The CRISPR Journal | EurekAlert …
EurekAlert (press release) This press release is issued on behalf of The CRISPR Journal, a peer-reviewed journal from Mary Ann Liebert Inc. dedicated to publishing outstanding research and commentary in all aspects of CRISPR and gene editing research. Bill Gates on What Gene Editing and CRISPR Means for Public …Foreign Affairs CRISPR might one day reverse devastating brain diseasesSTAT Researcher speeds up CRISPR’s gene editing ability – UPI.comUPI.com Phys.Org –News-Medical.net –Massive all 15 news articles » |
